Loading clinical trials...

RECRUITINGEARLY_PHASE1

Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

An Open, Single Center Exploratory Study to Evaluate Safety and Efficacy of NK520 for Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06541405•Base Therapeutics (Shanghai) Co., Ltd.

View on ClinicalTrials.gov

Summary

This study will evaluate the safety and efficacy of NK520 in the treatment of pediatric relapsed/refractory acute myeloid leukemia. NK520 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.

Detailed Description

This open label, single-arm study aims to evaluate the efficacy and safety of allogenic NK cells in pediatric relapsed/refractory acute myeloid leukemia. Allogenic NK cells will be infused once a week. After infusion, the investigators will observe the characteristics of dose limited toxicity (DLT), and determine the maximum tolerable dose(MTD). To provide basis for the dosage and treatment plan of cell products in follow-up clinical trials.

Eligibility

Age

6 - 18 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Participants must be between 6 and 18 years;
•2. Diagnostic Criteria: Meet the 2022 World Health Organization (WHO) diagnostic criteria for AML, unsuitable for current treatments or patients with relapsed/refractory AML after ≥2 lines of therapy. The definition of relapsed/refractory acute myeloid leukemia is based on the 2017 Chinese Guidelines for Diagnosis and Treatment: a. Relapsed AML: Diagnosis is confirmed when leukemia cells reappear in the peripheral blood or bone marrow blast cells exceed 5% after complete remission (CR) (excluding reasons such as bone marrow regeneration post-consolidation chemotherapy) or there is extramedullary infiltration by leukemia cells; b. Refractory AML: Initial cases unresponsive after two cycles of standard regimen treatment; recurrence within 12 months after CR and consolidation therapy; recurrence beyond 12 months with ineffectiveness of conventional chemotherapy; those who have relapsed twice or more; or persistent extramedullary leukemia;
•3. For participants under 16 years old, Lansky performance status must be ≥50%; for participants aged 16 or older, Karnofsky performance status must be ≥50%;
•4. Expected survival of at least 12 weeks;
•5. Normal Organ Function.

Exclusion Criteria

•1. Acute promyelocytic leukemia, chronic myeloid leukemia, acute mixed lineage leukemia, or known central nervous system leukemia;
•2. AML associated with congenital syndromes, such as Down syndrome, Fanconi anemia, Bloom syndrome, Kostmann syndrome, or congenital aplastic anemia;
•3. Severe bleeding tendency or coagulation disorders, or currently receiving thrombolytic therapy;
•4. HIV-infected individuals, or individuals with known active syphilis infection;
•5. Receipt of live attenuated vaccines within 2 weeks before the first dose or planned during the study period;
•6. Participation in another clinical trial and receipt of investigational drug within 4 weeks prior to the first dose;
•7. Receipt of immune-modulatory drugs (including thymosin, interferons, except for local use to manage conditions like pleural or ascites fluid) within 2 weeks before the first dose;
•8. At screening, positive hepatitis B or C viral markers as follows:
•* HBsAg positive with serum HBV-DNA level ≥1×10\^3 copies/mL or above normal range;
•* Positive for HCV antibodies;
+1 more criteria

Locations (1)

Shanghai Children's Medical Center

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

July 1, 2024

Primary Completion Date

June 1, 2025

Completion Date

June 1, 2025

Last Updated

August 7, 2024

Enrollment

ESTIMATED participants

Conditions

Relapsed/Refractory Acute Myeloid Leukemia

Interventions

NK520

DRUG

Contacts

Jun Yan

CONTACT

13817651474 yanjun@basetherapeutics.com

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

NCT05143996

Relapsed/Refractory Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)

View study

RECRUITINGPHASE1

A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT05924750

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 7, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

Inclusion Criteria

Exclusion Criteria

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

LILRB4 STAR-T Cells in the Treatment of R/R AML/CMML

Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML